Cover Image
市場調查報告書

生物製藥的智慧財產權:策略性檢討

Biologics IP - A Strategic Review

出版商 Technical Insights (Frost & Sullivan) 商品編碼 370700
出版日期 內容資訊 英文 71 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物製藥的智慧財產權:策略性檢討 Biologics IP - A Strategic Review
出版日期: 2016年08月10日 內容資訊: 英文 71 Pages
簡介

本報告提供大醫藥品、生物科技企業13家公司的生物製藥相關的專利的相關調查,各製劑類型、治療領域的專利組合的製圖,競爭基準等彙整資料。

第1章 摘要整理

第2章 調查目的、背景

  • 調查目的
  • 生物製藥 vs 小分子
  • 大醫藥品製造商從小分子轉向生物製藥與其理由
  • 透過M&A獲得生物製藥的專門性的大醫藥品製造商

第3章 調查範圍、調查手法

第4章 13家醫藥品大公司的生物製藥的專利組合

  • 13家醫藥品大公司的競爭基準:生物製藥的專利組合

第5章 生物製藥的專利組合:概要

  • ROCHE
  • GSK
  • MERCK
  • SANOFI
  • NOVARTIS
  • BRISTOL-MYERS SQUIBB
  • AMGEN
  • NOVO NORDISK
  • PFIZER
  • ELI LILLY
  • ASTRAZENECA
  • BAYER HEALTHCARE
  • ABBVIE
    • 專利組合製圖:各生物製藥類型
    • 專利組合製圖:各治療領域

第6章 主要調查結果

第7章 附錄

  • 用語

第8章 關於FROST & SULLIVAN

目錄
Product Code: D6AE-01-00-00-00

Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics

This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.

Table of Contents

1 1.0 EXECUTIVE SUMMARY

  • 1.0 Executive Summary

2 2.0 RESEARCH OBJECTIVE AND BACKGROUND

  • 2.1 Research Objective
  • 2.2 Biologics versus Small Molecule
  • 2.3 Big Pharma Shifting Focus from Small Molecule to Biologics, Why?
  • 2.4 Big Pharma Gained Biologics Expertise through Mergers and Acquisitions (M&A)-Important Deals

3 3.0 RESEARCH SCOPE AND METHODOLOGY

  • 3.1 Research Scope and Concepts
  • 3.2 Analysis Approach
  • 3.3 Keywords and IPC Codes Used for Clustering by Biologics Type
  • 3.4 Therapeutic Areas Covered in the Study

4 4.0 BIOLOGICS PATENT PORTFOLIOS OF THE TOP 13 MAJOR PHARMA COMPANIES

  • 4.1 Competitive Benchmarking of the Top 13 Major Pharma Companies Based on Their Biologics Patent Portfolios, 1996-2015

5 5.0 OVERVIEW OF BIOLOGICS PATENT PORTFOLIO5.1 COMPANY 1: ROCHE

  • 5.1.1 Mapping of Roche's Patent Portfolio by Biologics Type
  • 5.1.2 Mapping of Roche's Patent Portfolio by Therapeutic Area

6 5.2 COMPANY 2: GSK

  • 5.2.1 Mapping of GSK's Patent Portfolio by Biologics Type
  • 5.2.2 Mapping of GSK's Patent Portfolio by Therapeutic Area

7 5.3 COMPANY 3: MERCK

  • 5.3.1 Mapping of Merck's Patent Portfolio by Biologics Type
  • 5.3.2 Mapping of Merck's Patent Portfolio by Therapeutic Area

8 5.4 COMPANY 4: SANOFI

  • 5.4.1 Mapping of Sanofi's Patent Portfolio by Biologics Type
  • 5.4.2 Mapping of Sanofi's Patent Portfolio by Therapeutic Area

9 5.5 COMPANY 5: NOVARTIS

  • 5.5.1 Mapping of Novartis's Patent Portfolio by Biologics Type
  • 5.5.2 Mapping of Novartis's Patent Portfolio by Therapeutic Area

10 5.6 COMPANY 6: BRISTOL-MYERS SQUIBB

  • 5.6.1 Mapping of Bristol-Meyers Squibb's Patent Portfolio by Biologics Type
  • 5.6.2 Mapping of Bristol-Meyers Squibb's Patent Portfolio by Therapeutic Area

11 5.7 COMPANY 7: AMGEN

  • 5.7.1 Mapping of Amgen's Patent Portfolio by Biologics Type
  • 5.7.2 Mapping of Amgen's Patent Portfolio by Therapeutic Area

12 5.8 COMPANY 8: NOVO NORDISK

  • 5.8.1 Mapping of Novo Nordisk's Patent Portfolio by Biologics Type
  • 5.8.2 Mapping of Novo Nordisk's Patent Portfolio by Therapeutic Area

13 5.9 COMPANY 9: PFIZER

  • 5.9.1 Mapping of Pfizer's Patent Portfolio by Biologics Type
  • 5.9.2 Mapping of Pfizer's Patent Portfolio by Therapeutic Area

14 5.10 COMPANY 10: ELI LILLY

  • 5.10.1 Mapping of Eli Lilly's Patent Portfolio by Biologics Type
  • 5.10.2 Mapping of Eli Lilly's Patent Portfolio by Therapeutic Area

15 5.11 COMPANY 11: ASTRAZENECA

  • 5.11.1 Mapping of AstraZeneca's Patent Portfolio by Biologics Type
  • 5.11.2 Mapping of AstraZeneca's Patent Portfolio by Therapeutic Area

16 5.12 COMPANY 12: BAYER HEALTHCARE

  • 5.12.1 Mapping of Bayer HealthCare's Patent Portfolio by Biologics Type
  • 5.12.2 Mapping of Bayer HealthCare's Patent Portfolio by Therapeutic Area

17 5.13 COMPANY 13: ABBVIE

  • 5.13.1 Mapping of AbbVie's Patent Portfolio by Biologics Type
  • 5.13.2 Mapping of AbbVie's Patent Portfolio by Therapeutic Area

18 6.0 KEY FINDINGS

  • 6.1 Key Findings
  • Legal Disclaimer

19 7.0 APPENDIX

  • 7.1 Acronyms

20 8.0 THE FROST & SULLIVAN STORY

  • 8.1 The Frost & Sullivan Story
  • 8.2 Value Proposition: Future of Your Company & Career
  • 8.3 Global Perspective
  • 8.4 Industry Convergence
  • 8.5 360° Research Perspective
  • 8.6 Implementation Excellence
  • 8.7 Our Blue Ocean Strategy
Back to Top